Sens group concluded with, Future studies are needed to determine more specific safe discontinuation intervals and preprocedural fasting times for these agents prior to elective procedures under anesthesia
Pharmaceutical Executive: How do you see the FDAs intent to take action against non-FDA-approved GLP-1 products affecting the competitive landscape for obesity and diabetes therapies in the near term
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal (2025) 6
But they tend to be mild. Orlistat has some unique (and unpleasant) side effects, like gas, oily or loose stools, and oily spotting (since your body has to get rid of the excess fat that it's not absorbing)
2016;113(19):E2655E2664
Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes